Search

Displaying results 5471 - 5480 of 10000 in total
  1. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. … Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

    Synonyms: (S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
  2. Drug

    OP-145

    go.drugbank.com/drugs/DB05672
    Experimental

    OP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.

    Synonyms: (4S)-4-(((2S)-2-((2-(((2S,3S)-2-ACETAMIDO-3-METHYL-PENTANOYL)AMINO)ACETYL)AMINO)-6-AMINO-HEXANOYL)AMINO)-5-(((1S)-2-(((1S)-5-AMINO-1-(((1S)-1-(((1S,2S)-1-(((1S)-1-(((1S)-1-(((1S)-1-(((1S,2S)-1-(((1S)-5, -AMINO-1-(((1S)-1-(((1S)-1-BENZYL-2-(((1S)-1-(((1S)-1
  3. Drug

    Pyrvinium

    go.drugbank.com/drugs/DB06816
    ApprovedInvestigationalWithdrawn

    Pyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate.

  4. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. … It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.

  5. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity

  6. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  7. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

  8. Drug

    Floxuridine

    go.drugbank.com/drugs/DB00322
    ApprovedInvestigational

    An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. … When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate.

  9. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  10. Drug

    AVE9633

    go.drugbank.com/drugs/DB06318
    Investigational

    AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.